Join to View Full Profile
2950 Cleveland Clinic BlvdWeston, FL 33331
Phone+1 954-659-5840
Fax+1 954-659-5833
Dr. Nagarajan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Arun Nagarajan is an oncologist based in Weston, FL, specializing in cancer genetics, gastrointestinal cancer, hematologic oncology, and complementary and integrative medicine. He completed his fellowship in hematology and medical oncology at the University of Arkansas for Medical Sciences and has extensive experience in various types of cancer, including hepatocellular carcinoma and colorectal cancer. Dr. Nagarajan has contributed to several publications on cancer treatment outcomes and has been involved in clinical trials targeting specific genetic mutations in tumors. He holds CMS Meaningful Use Stage 1 Certification, recognizing his proficiency with electronic health records.
Education & Training
University of Arkansas for Medical SciencesFellowship, Hematology and Medical Oncology, 2001 - 2004
West Suburban Medical CenterResidency, Internal Medicine, 1999 - 2001
Rush University Medical CenterInternship, Internal Medicine, 1998 - 1999
Adichunchanagiri Institute of Medical SciencesClass of 1996
Certifications & Licensure
FL State Medical License 2015 - 2026
WV State Medical License 2004 - 2017
IL State Medical License 2000 - 2005
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2017
Clinical Trials
- Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI Start of enrollment: 2013 May 31
- Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Start of enrollment: 2015 Nov 19
Publications & Presentations
PubMed
- Outcomes reported in randomized controlled trials of rectal cancer treatment: A scoping review for the CORRECT initiative.Richard Garfinkle, Saba Balvardi, Heather Carmichael, Risa Shorr, Manju George
European Journal of Surgical Oncology. 2026-01-17 - Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients with Resected Stages I-III Colon Cancer.Stacey A Cohen, Vasily N Aushev, George Laliotis, Iktej S Jabbal, Arun Nagarajan
Annals of Surgery. 2025-08-07 - 5 citationsNeoadjuvant chemotherapy improves overall survival in stage III but not in stage II colon cancer: A propensity score-matched analysis of the National Cancer Database.Nir Horesh, Sameh Hany Emile, Michael R Freund, Zoe Garoufalia, Rachel Gefen
Surgery. 2025-07-01
Journal Articles
- E3611- A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High Dose Interferon-α2b in Advanced MelanomaArun Nagarajan, Mark R Albertini, Stuart Wong, Noel Laudi, Robert M Conry, Clinical Cancer Research
Committees
- Hereditary Pancreatic cancer PCO panel, ASCO 2016 - Present
Research History
- Co-Principal Investigator for ECOG trials at Charleston Area Medical Center2004 - 2016
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
